Monday, 18 May 2020

Esophageal Cancer Market By Key Vendors, Regions, Trends with Industry Study & Forecast to 2023

Esophageal Cancer Market Scenario:
Cancer is one of the leading causes of death worldwide and is expected to witness the expansion of patient population in the years to come. One of the types of cancer that affect the food pipe connecting the mouth and stomach is the esophageal cancer which is majorly prevalent among the older adults belonging to 55 years and above age group. Market Research Future (MRFR) has found out that the global esophageal cancer treatment market is projected to grow at a compound annual rate of 8.7% during the forecast period 2017 to 2023. It is underlined in the report that the market is anticipated to scale a decent valuation of USD 1000.1 Mn towards the close of 2023.
The rising burden of cancer has paved the way for innovation in the market. It is one of the prime areas of research in the medical field. With the increasing number of drug patent applications in conjunction with the rising count of clinical trials, the esophageal cancer market size is expected to witness a boom over the next couple of years. Key players are anticipated to exponentially invest in the development of more effective treatments which is forecasted to aid the proliferation of the esophageal market in the foreseeable future.
Addiction to tobacco, betel nuts, etc. is the key factor responsible for triggering esophageal cancer. Increasing shift towards a sedentary lifestyle has led to an increase in addiction problems among the masses. This, in turn, is expected to catalyze the growth of patient population. The future trajectory of the esophageal market is likely to remain highly lucrative over the next couple of years.
People are getting increasingly aware of the availability of treatments which is poised to aid market expansion. The support extended by governments in conjunction with the early detection of the disease has unleashed massive opportunities for the market players. It is anticipated to augment the esophageal cancer market in the long run.
Segmentation:
The global esophageal cancer market is segmented on the basis of type. Based on the type, the market has been segmented as esophageal squamous-cell carcinoma, esophageal adenocarcinoma and others. Based on the phases, the market has been segmented as phase I, phases II and phases III. Based on the treatment, the market has been segmented as surgery, chemotherapy and radiotherapy and other.
Intended Audience
  • Global Esophageal cancer solutions providers, manufacturers & suppliers
  • Research and development (R&D) companies
  • Market research and consulting service providers
  • Academic institutes and universities
Regional Analysis
The market of esophageal cancer is much higher in the Americas region attribute to high rate of tobacco, alcohol, very hot drinks, poor diet, and chewing betel nut. According to report published by American Cancer Society, in 2018, it is estimated that around 17,290 new cases of esophageal cancer diagnosed in Americas which include 13,480 of men and 3,810 of women and around 15,850 will be die. Additionally, In the United States, up to 200,000 people die each year from smoking-related illnesses that leads to incidence of esophageal cancer in this region. The government have more focus towards research and development for introducing the best treatment for their population.
Asia Pacific region are considering the growing market, owing to presence of huge population suffering with esophageal cancer. Whereas country like India and china are considering fastest growing region due to the high rate of tobacco and alcohol consumption which leads the incidence of esophageal cancer, additionally they are open to adopt new technology, and best treatment option from developed countries in order to improve the quality of life for their citizen. Whereas, the Middle East and Africa have low market due to his incapability of investment, Moreover, developing countries are still focusing on new drugs for the treatment of esophageal cancer, this gap between the developed and developing countries will present significant growth opportunity for the esophageal cancer market players in the coming years.
Europe is also consider huge market for esophageal cancer players, owing to present of huge population affected with disease. According to Cancer Research U.K, in 2014, esophageal cancer holds 2 percent of total cancer cases in United Kingdom. Government are more focusing to educate their public in order to minimize the patient’s population by educating them about the side effect of tobacco, alcohol etc.
Key players of Global Esophageal cancer Market:
  • Amgen
  • Eli Lilly and Company,
  • Hoffmann-La Roche,
  • Bristol-Myers Squibb Company,
  • Boehringer Ingelheim GmbH,
  • Bristol-Myers Squibb,
  • GlaxoSmithKline Plc.,
  • Novartis AG,
  • Johnson & Johnson,
  • Gilead Sciences,
  • Merck & Co.
Posted by at No comments:

Africa Malaria Diagnosis & Treatment Market By Key Vendors, Regions, Trends with Industry Study & Forecast to 2023

Market Synopsis of Africa Malaria Diagnosis & Treatment Market:
Malaria is an infectious disease caused by parasitic protozoa of the Plasmodium type. The symptoms include fever, fatigue, vomiting, and severe headaches and may lead to seizures, coma, or even death if untreated. Malaria is primarily a disease of the tropical and subtropical regions. The carrier of malaria is the female anopheles mosquito and hence there is a seasonal variation in the cases of malaria. Most cases of malaria are caused by P. falciparum because other types of plasmodium such as P. vivax, P. ovale, and P. malariae generally cause a milder form of malaria.
According to World Health Organization (WHO), the global incidence of malaria between 2010 and 2015, fell by 21% and the malaria mortality fell by 29%. However the African region carries a disproportionately high share of the global malaria burden and accounted for 90% of malaria cases and 92% of malaria deaths worldwide and sub-Saharan Africa accounted for 76% of malaria cases and 75% deaths globally.
Thus, unmet medical needs is the single most important driver of malaria. Other important market drivers are the hot and humid climatic conditions of certain parts of Africa, presence of population groups at higher risk of contracting malaria such as infants, children under 5 years of age, patients with low immunity such as those with HIV/AIDS, mobile populations and travelers.
The growth of government programs against malaria and the support given by international bodies such as WHO is also a market driver. The market barriers include high cost of imported malaria diagnostic kits, low penetration of healthcare in Africa, low per capita income, low number of healthcare professionals in Africa etc. The political causes include massive corruption, low political power of citizens especially in nondemocratic nations, civil war in regions such as Malawi etc.
Taking all factors into consideration, we expect the Africa malaria  diagnosis market to reach around $ 2418.92 million from $ 550 million in 2017, by the end of the forecast period at a CAGR of ~ 28.0 %. While the malaria treatment market will grow by a CAGR of 8.1% to reach around $ 7180.7 million from $ 4500.0 million in 2016.

Study Objectives for Africa Malaria Diagnosis & Treatment Market:
  • To provide detail analysis of the market structure along with forecast for the next 6 years of the various segments and sub-segments of the Africa malaria diagnosis & treatment market
  • To provide insights about factors affecting the market growth
  • To analyze the market based on various factors - price analysis, supply chain analysis, porters five force analysis etc.
  • To provide historical and forecast revenue of the market segments and sub-segments for Africa malaria diagnosis & treatment market
  • To provide country level analysis of the market with respect to the current market size and future prospective
  • To provide country level analysis of the market for segments by product type, by technique, malarial parasite and other sub segments.
  • To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market
  • To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments.
Intended Audience
  • Malaria Diagnostics Manufacturers and Suppliers
  • Medical Drugs Manufacturers and Suppliers
  • Private Research Laboratories
  • Research and Development (R&D) Companies
  • Market Research and Consulting Service Providers
  • Government Research Laboratories
  • Contract Manufacturing Organizations

Key Players for Africa Malaria Diagnosis & Treatment Market:
Some of the key players in this market are: Alere Inc., Access Bio Inc., Premier Medical Corporation, Beckman Coulter/Danaher, bioMerieux, Novartis Diagnostics, Siemens Healthcare, Bio-Rad Laboratories, Cipla Inc., Ipca Laboratories Ltd., Uni-Med India, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Sanofi among others.
Segments:
Africa Malaria Diagnosis & Treatment Market has been segmented on the basis of technique which comprises rapid diagnostic tests (RDT’S), molecular diagnostics and microscopy. On the basis of malarial parasite; market is segmented into plasmodium falciparum, plasmodium vivax, plasmodium malariae and plasmodium ovale.

Regional Analysis of Africa Malaria Diagnosis & Treatment Market:
The healthcare sector of Africa is divided between private and state. The public healthcare expenditure accounts for approximately 48 % of total health expenditure in 2014 with variation in different countries. Local manufacturing represents a poor outlook which is limited to consumables and ordinary articles and there are a handful of high tech devices manufacturers. Africa is extremely dependent on imports for medical devices and imports account for approximately 90 % of total market for medical devices and Chinese medical device suppliers dominate the scenario. Among the regions of Africa, South Africa and Egypt account for 40 % of market. Other important nations are Nigeria, Morocco and Algeria. Collaboration with large global companies and technical transfer will remain the key strategy for developing the regional African market as can be seen by the example of China.

The report of Africa Malaria Diagnosis & Treatment Market of Market Research Future comprises extensive primary research along with the detail analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regionsTop of Form
Posted by at No comments:

2020 Latest Study explores the U.S. Personalized Medicine Market Witness Highest Growth in near future by 2023

Market Synopsis of U.S. Personalized Medicine Market:
An expert on premium research reports, Market Research Future has added a report titled " U.S. Personalized Medicine Market Research Report - Forecast To 2023" to its offering. The report provides an in-depth analysis of regional data and an accurate projection of the market size and share of the Top 10 market players across the globe.
The Personalized Medicine Market is the most recent trend in the multibillion–dollar molecular diagnostics industry. Pharmaceutical and biotechnology companies are increasingly turning to personalized medicine in order to improve the drug development process and also to speed up the approval or sanction of new drugs.
The U.S. Personalized Medicine market has been evaluated as average growing market and expected that the market will reach high growth figures in coming years. A factsheet published by the WHO states that about 17.5 million people die due to cancer and other diseases every year, which is about 31% of the deaths across the globe. These alarming statistics shows the obvious reason for growth of market with the U.S. Personalized Medicine market analysis. Major factors driving the U.S. Personalized Medicine market growth include growing occurrence of autoimmune diseases during the forecast period and various other disease.
U.S personalized medicine market is expected to grow at the CAGR of 7.5% during the forecasted period.
Various trends are responsible for influencing the growth trajectory of the US personalized medicine market. Personalized medicine promises enormous potential in the treatment of cancer. Personalized medicine has entered the mainstream in the treatment of oncology diseases and is changing the way such diseases are identified, treated and classified. According to the World Health Organization (WHO), cancer is one of the prime reasons for 31% of the deaths globally and each year about 17.5 Mn people die due to cancer. Surging prevalence of cancer across the US is a prime reason for the growth of the US personalized medicine market.
Strong research & development activities in the field of personalized medicine by industrial, academic, and government agencies continue to remain strong in the region which also supports the growth of the US personalized medicine market.
Increasing incidences of autoimmune diseases stimulate the growth of the US personalized medicine market. Also, the government in the US is extending its support in the form of funding for R&D activities; favorable NIH policies create a conducive environment for the growth of the US personalized medicine market.
Furthermore, a growing number of companies from outside the health industry are entering the personalized medicine space which is likely to provide an impetus to the growth of the US personalized medicine market. 
Industry Updates
  • In December 2018, researchers at the University of Utah developed a novel personalized medicine tool for inherited colorectal cancer syndrome. The results for the same was published in the journal Genetics in Medicine.
  • In December 2018, researchers at the Columbia University have made advancements in personalized medicine that can be helpful in the treatment of kidney diseases.
Segmentation
The US personalized medicine market has been segmented based on product, application, and end user. By product, the US personalized medicine market has been segmented into diagnostic, therapeutics, medical care and nutrition, and wellness and others. The diagnostic and therapeutic segment accounts for the largest share of the market.
By application, the US personalized medicine market has been segmented into diagnosis and intervention, drug development and usage, cancer genomics and others.
By end user, the US personalized medicine market has been segmented into hospitals, molecular diagnostic laboratories and testing centers, academic institutes, bio & health informatics companies, and others. End user-wise, the hospitals segment commands the largest share of the market owing to growing usage in hospitals. The molecular diagnostic laboratories and testing centers segment is the second largest segment.
Competitive Landscape
Personalized medicine is presenting new challenges as well as opportunities to the market players who are continually endeavoring make their mark in the market. Collaborations through mergers, acquisitions, partnerships, and others are key strategies utilized by the market participants to stay competitive and improve their product offerings. Sanofi, Pfizer Inc., Laboratory Corporation of America, Abbott, Becton Dickinson & Co., Quest Diagnostics, GE Healthcare,
CardioDx Inc., Asuragen Inc., Bristol-Myers Squibb, Siemens Healthcare Diagnostics Inc., are the notable players in the US personalized medicine market.
Posted by at No comments:

Global India CRO Market Drivers, Segmentations, Key Players, Analysis & Forecast 2020 - 2023

Market Synopsis of India CRO Market:
A Contract Research Organization (CRO) offers outsourced services to support R&D functions for pharmaceutical, biotechnology, and health companies. The services may be clinical research, product development such as drug development or process development such as bio analytical assay development. A CRO may also provide management services such as clinical trials management, and pharmacovigilance.
According to the analysis offered by Market Research Future (MRFR), the India CRO market has been presumed to flourish at a CAGR of 12.0% during the forecast period with overview of top cro companies in India.
The two important factors that are making India a favorable market for CRO include India’s acceptance of international guidelines and intellectual property rights. Other factors include the availability of the largest pool of patients and large hospitals, educated and accessible human resource (HR), low operational cost due to cheap HR, and lastly the presence of diverse types of climatic conditions that allow stability studies to be performed with ease in one destination. Some legal factors that favor the growth of India CRO market are efforts by the regulatory authorities such as Department of Biotechnology (DBT), Director Controller General of India (DCGI), Directorate General of Foreign Trade (DGFT), and Indian Council of Medical Research (ICMR).
The market constraints that can hamper the growth of India CRO market include growing concern for security especially data security and patient security and lack of collaboration between universities and industry etc. Sometimes, some unethical Indian CROs make dishonest comprises which creates trust issues among potential clients for CROs and hurts the market.
Segments:
India CRO market has been segmented on the basis of service types which comprises clinical trials, product development, process development, post-marketing surveillance, quality monitoring and others. On the basis of therapeutic application; market is segmented into oncology, cardiovascular, neurology, nephrology and urology, and others. On the basis of end users; market is segmented into pharmaceutical/biopharmaceutical companies, medical devices companies and academic institutes.
Regional Analysis of India CRO Market:
The western and southern regions of India hold a strong position in the CRO market due to their better infrastructure, education and salubrious climate. However the northern regions have started growing and catching up due to larger and more diverse genetic pool and the concentration of regulatory bodies in northern India. The faster growth of hospitals in northern India is favoring the CRO market and has led to this shift. The growth of diseases needing specialized care and treatments such as cancer is booming the CRO market of this segment at a faster pace than other segments.
India is emerging as a top destination for contract research organizations for the following reasons
  • India’s acceptance of International guidelines and intellectual property rights
  • Presence of diverse types of climatic conditions thus allowing stability studies to be performed with ease in one destination
  • Educated and accessible human resource in India
  • Presence of diverse ethnic pool thus enabling diverse sample for clinical trials
  • Low operational cost due to cheap human resource
  • Availability of largest pool of patients and large hospitals

Indian CRO Market - Competitive Landscape
The India CRO market is dominated by multinational CROs, followed by India CROs, multinational pharmaceutical companies, and Indian pharmaceutical companies. Among these, the Indian pharmaceutical companies are mainly engaged in conducting local trials.
In March 2018, The world's largest healthcare information provider and contract medical research, IQVIA, has recently stated that it is preparing to initiate outright buyouts to investments in start-ups for technologies that based on artificial intelligence and data analytics, while also considering those related to the healthcare sector as it converts into a "Human Data Science Company". Further, the company also stated that the investments in the future will be more directed towards development in the Asia Pacific region that includes China, India, Japan and South Korea where the company forecasts increasing demand for its services in the coming years.
In March 2018, Syngene International has entered into a multiyear R&D agreement with GlaxoSmithKline plc. The companies with this collaboration are focus to accelerate the discovery of new drug candidates using Syngene discovery services platforms.
Posted by at No comments:

Carcinoid Syndrome Management Market By Key Vendors, Regions, Trends with Industry Study & Forecast to 2023

Market Scenario:
Carcinoid syndrome comprises of signs and symptoms including flushing of the face, debilitating diarrhea, asthma caused due to vasoconstriction, intestinal bleeding, fast heartbeat, shortness of breath, sweating, unexplained weight gain etc. which are settled secondary to carcinoid tumor. The management or treatment of carcinoid syndrome often requires palliative and supportive care. Management of carcinoid syndrome involves drug therapy or surgical removal of carcinoid tumor from the organ.
Increasing incidence of hormonal disorders, growing smoking habits, levels of carcinogen in highly developed countries etc. are the major driving factor, driving the growth of the market. The only factor restraining the growth of global carcinoid syndrome management market is that no availability of drugs approved to manage carcinoid syndrome.
Segmentation:
The global carcinoid syndrome management market is segmented on the basis of organs affected by the disease, treatment procedures and end users. Based on organs affected by the disease, the market has been segmented into small intestine, lungs, rectum, appendix, colon, stomach, pancreas, liver and others. Based on treatment type, the market has been segmented intochemotherapy, biological therapy, and hepatic artery embolization agents. Further on the basis of end users the market has been segmented as hospital, clinics, and cancer institute and treatment centers.
Key players
  • Novartis International AG (Sandoz)
  • Pharmascience Inc.
  • Omega Laboratories Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Mylan N.V.
  • Ipsen Biopharmaceuticals, Inc.
  • Sirtex Medical Limited
  • BTG International Ltd.
  • Wockhardt Ltd.
  • Sun Pharmaceutical Industries Limited
Study Objectives:
  • To provide detail analysis of parent market and the changing market dynamics of the industry.
  • To provide detail analysis of the market structure along with estimated future growth forecast about various segments and sub-segments of the global carcinoid syndrome management market.
  • To provide in depth market segmentation and historical, current and projected market size in terms of value and volume with respect to four main geographies and their countries- Americas, Europe, Asia-Pacific, and Middle East & Africa.
  • To provide country level analysis of the market with respect to the current market size and future growth prospect.
  • To provide detailed analysis on recent industry trends and developments, strategies of key players and competitive landscape of the market.
  • To track and analyze developments which are competitive in nature such as joint ventures, strategic alliances, mergers and acquisitions, new product developments along with research and developments currently taking place  in the global  Carcinoid Syndrome Management.
Regional Analysis
The Global Carcinoid Syndrome Management is segmented on the basis of regions, into North America, Europe, Asia-Pacific, and Middle East & Africa. America accounts for the largest market share of the Global Carcinoid Syndrome Management by region in 2016. High per capita healthcare expenditures followed by increasing awareness of the diseases and presence of the developed healthcare sector are the major drivers for the market growth during the forecast period. Followed by the North America, Europe holds the second largest market. Asia pacific is the fastest growing region. However, the Middle East and Africa region holds the least share of the global market, especially due to the presence of the poor economies within the Asia Pacific region. In the Middle East & African region, the Middle East holds the largest market share.
Posted by at No comments:

2020 Latest Study explores the CBCT Dental Imaging Market Witness Highest Growth in near future by 2023

Market Scenario:
Dental cone beam computed tomography (CT) is a special type of x-ray equipment used when regular dental or facial x-rays are not sufficient. The technology is used to produce three dimensional (3-D) images of the teeth, soft tissues, nerve pathways and bone in a single scan. The CBCT dental imaging industry is growing rapidly. The increasing use of 3D radiographic imaging in orthodontics and increasing adoption of CBCT imaging by dental professionals has boosted the revenue of this market. 
The U.S., India & Europe market is expected to reach USD 565.3 million by the end of the forecast period due to rising CBCT Dental Imaging Market Trends and is expected to grow at a CAGR of 9.8%.
Key Finding
  • The U.S., India & Europe CBCT dental imaging market and is expected to reach USD 565.3 million by 2023.
  • Regionally, U.S. holds the largest CBCT dental imaging market share of U.S., India & Europe CBCT dental imaging market and is expected to reach USD 280.9 million by 2023.
  • India market is expected to be the fastest growing market, and expected to grow at a CAGR of 10.3% from 2016 to 2023
Key Players for U.S., India & Europe CBCT dental imaging market:
Some of the key players in this market are: Carestream Health (US), Dentsply Sirona (US), FONA Dental, S.R.O., Gendex, Imaging Sciences International, LLC (US), J.MORITA MFG.CORP. (Japan), KaVo Dental GmbH (Germany), NewTom, Planmeca OY, Prexion (US), Sinclair Dental/Dentaire (Canada), SOREDEX (Finland), Vatech Networks (Republic of Korea) and others.
Segments:
U.S., India & Europe CBCT dental imaging market has been segmented on the basis of type of detector which comprises of flat panel detectors, image intensifier. On the basis of application the market is segmented into dental implants, endodontics, orthodontics and others. On the basis of end users the market is segmented into hospitals & dental clinics, academic & research institutes and others.
Regional Analysis of U.S., India & Europe CBCT dental imaging market:
U.S. is the largest market for CBCT Dental Imaging market. The U.S. market for CBCT dental imaging is expected to grow at a CAGR of 9.5% and is expected to reach at USD 280.9 Million by the end of the forecast period.
Europe is the second-largest market for CBCT dental imaging which is expected to grow at a CAGR of 10.0%. India region is expected to be fastest growing region in CBCT dental imaging market.
The report for U.S., India & Europe CBCT Dental Imaging Market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions
Posted by at No comments:

Sunday, 17 May 2020

Anti-Hypertensive Drugs Market Covering Growth Inclinations & Development Strategies until 2022

According to a recent study report published by the Market Research Future, The global market of  Anti-Hypertensive Drugs was valued at $32.2 billion in 2015, and is projected to reach $ USD 41.2 billion by 2023. Thus the anti-hypertensive drugs market size is anticipated to observe a sluggish growth; at a CAGR of 2.73% during 2016 to 2022.
Anti-Hypertensive Drugs are used to treat hypertension (high blood pressure). Hypertension is a state of chronic elevated arterial blood pressure at or greater than 140/90 mm Hg for adults. Hypertension is one of the most powerful risk factors for cardiovascular morbidity and mortality. There exact cause of hypertension is unknown but is said that unhealthy, heady lifestyle and ageing mirror such disorders as “Hypertension”.
The major market driving factors for secondary hypertension are greater detection and early diagnosis. Rise in the prevalence diseases such as kidney problems, thyroid problems, adrenal gland tumours, heart ailments, chronic alcohol use etc. in which anti-hypertensive drugs are used; are some of the other factors driving the growth of the Anti-Hypertensive Drugs market. The constraints however are overwhelming and include patent expiries such as Actelion's Tracleer (2015), and United Therapeutic's Remodulin (2014). Other blockbuster’s such as Novartis's Diovan and Exforge, Sanofi Aventis's Avapro (2012) etc are also off-patent.
Many antihypertensive drugs have their primary action on systemic vascular resistance. Some of these drugs produce vasodilation by interfering with sympathetic adrenergic vascular tone (sympatholytics) or by blocking the formation of angiotensin II or its vascular receptors. Other drugs are direct arterial dilators, and some are mixed arterial and venous dilators. Although less commonly used because of a high incidence of side effects, there are drugs that act on regions in the brain that control sympathetic autonomic outflow. By reducing sympathetic efferent activity, centrally acting drugs decrease arterial pressure by decreasing systemic vascular resistance and cardiac output.
Some antihypertensive drugs, most notably beta-blockers, depress heart rate and contractility (this decreases stroke volume) by blocking the influence of sympathetic nerves on the heart. Calcium-channel blockers, especially those that are more cardioselective, also reduce cardiac output by decreasing heart rate and contractility. Some calcium-channel blockers (most notably the dihydropyridines) are more selective for the systemic vasculature and therefore reduce systemic vascular resistance.
Segmentation
The Anti-Hypertensive Market can be segmented in to 4 key dynamics for the convenience of the report and enhanced understanding; 
Segmentation By Pharmacological Class               : Comprises Diuretics, ACE Inhibitors, Calcium Channel Blockers, Adrenergic Blocker and other. 
Segmentation By Hypertension Type                      : Comprises Systemic and Pulmonary Hypertension Drugs and other. 
Segmentation By Disease Source                              : Comprises Primary and Secondary. 
Segmentation By Regions                                            : Comprises Geographical regions - North America, Europe, APAC, including Anti-Hypertensive Drugs Market in India and Rest of the World.
Regional Analysis
The antihypertensive drugs market covers growth drivers in the following regions, namely Americas, Europe, Asia Pacific (APAC), and the Middle East & Africa (MEA). The Americas accounted for a large market share owing to high prevalence of hypertension linked to cardiovascular and renal disorders. Drives by government and non-government organizations for creating awareness of the medical condition are likely to bolster the revenue of the antihypertensive drugs market in Americas.
The Europe region was the second-largest due to rise of cardiovascular diseases, unhealthy diets, and increase noticed in obesity levels of patients. According to the European Heart Network in 2017, heart diseases accounted for 3.9 million deaths. Germany, France, and the U.K. are expected to be the prime contributors to the antihypertensive drugs market in Europe.
The APAC region is projected to exhibit a robust pace owing to increased healthcare budget and rise in disposable income levels of patients. The setup of research and development centers to fast-track the commoditization of drugs for treating hypertension is likely to boost the APAC antihypertensive drugs market.
Key Players
Novartis AG, Daiichi Sankyo Company Limited, Acetelion Ltd, Boehringer Ingelheim, Sanofi S.A., Astra Zeneca plc, Ranbaxy Laboratories Limited, Inc., Takeda Pharmaceuticals Company Limited, Pfizer Inc. are some of the prominent players at the forefront of competition in the Global Market of Anti-Hypertensive Drugs and are profiled in MRFR Analysis.
Posted by at No comments:
Subscribe to: Posts (Atom)